CANbridge Pharmaceuticals Inc. has appointed Marcelo Cheresky to the position of Senior Vice President, Rare Disease Commercial Operations, effective as of July 16, 2019.
 
Mr. Cheresky has nearly 20 years’ business leadership experience in the biotechnology industry. Most recently, he was Vice President, Emerging Markets at Bioverativ, a Sanofi company, in Boston, MA, where he established regional structures for emerging markets and oversaw country launches in multiple emerging markets, including Australia, Columbia and Taiwan.  
 
“We are very pleased to have a leader of such high-caliber experience heading up the CANbridge rare disease commercial team as we submit the first CANbridge rare disease NDA, for Hunterase, in China,” said James Xue, PhD, Founder, Chairman and CEO, CANbridge Pharmaceuticals. “Marcelo’s strong international experience, particularly in emerging markets, proven commercial strategy success and sophisticated grasp of the nuances of managing a global pharmaceutical enterprise, will put CANbridge in good stead as we build our RD pipeline targeting China and other international markets.”